We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Long, Noncoding RNA Linked to Lung Cancer Metastasis

By LabMedica International staff writers
Posted on 20 Feb 2013
A recent paper described the functional significance of the long, noncoding RNA (lncRNA) MALAT1 in the process of lung cancer metastasis.

The vast majority of RNA molecules are transcribed by DNA segments that do not code for proteins. More...
These RNAs, which arbitrarily have been defined as containing more than 200 nucleotides, are called long, noncoding RNAs and are clearly differentiated from small, inhibitory RNAs such as short, inhibitory RNA (siRNA) and microRNA (miRNA).

MALAT1 (metastasis associated lung adenocarcinoma transcript 1) also known as NEAT2 (noncoding nuclear-enriched abundant transcript 2) is a large, infrequently spliced noncoding RNA. This molecular species is expressed in the nucleus and is highly conserved among mammals. It is associated with metastasis, and positively regulates cell motility via the transcriptional and/or post-transcriptional regulation of motility-related genes.

To study the role of MALAT1 in metastasis investigators at the German Cancer Research Center (Heidelberg) developed a MALAT1 knockout model in human lung tumor cells by genomically integrating RNA destabilizing elements using zinc finger nucleases that destroyed molecules of MALAT1 as soon as they were manufactured. In this manner, the investigators were able to silence MALAT1 expression by reducing the level of this molecular species in lung cancer cells by more than 1,000-fold.

The investigators reported in the December 14, 2012, online edition of the journal Cancer Research that the MALAT1-deficient cells were impaired in migration and formed fewer tumor nodules in a mouse xenograft.

Mice that had been injected with human lung cancer cells were treated with antisense oligonucleotides directed at MALAT1. This treatment prevented metastasis formation after tumor implantation. The animals' lungs showed fewer and smaller tumor nodules than those of control animals that had not been given the antisense nucleotides.

"The more MALAT1 tumor cells produce, the higher the odds for metastasis and a very unfavorable course of the disease," said senior author Dr. Sven Diederichs, a group leader in molecular RNA biology and cancer at the German Cancer Research Center. "Ten years after we discovered MALAT1 as a predictive marker in lung cancer, we now understand how this noncoding RNA influences metastasis. Moreover, this RNA has turned out to be a potential target for an innovative treatment with antisense RNAs."

Related Links:
German Cancer Research Center



Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
POC Immunoassay Analyzer
Procise DX
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: NeoCircle Study Synopsis (George, A.M., Chen, Y., Gladchuk, S. et al. EMBO Molecular Medicine (2026). DOI: 10.1038/s44321-026-00447-z)

Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.